Beta-blocker therapy and all-cause mortality after a coronary event: A matched nested case-control study using the Victorian Cardiac Outcomes Registry linked data

Current Problems in Cardiology 2026 Open access

Read full text
Authors: Pilar Cataldo-Miranda, Harvey Jia Wei Koh, Dion Stub, Sophia Zoungas, David M. Kaye, Danijela Gašević, Angela Brennan, Diem Dinh, Jeffrey Lefkovits, Shane Nanayakkara, Derek P. Chew, Stella Talic
DOI: 10.1016/j.cpcardiol.2026.103340
Cited by: 1
References: 29

Abstract

AIMS: Beta-blocker therapy has traditionally been recommended following coronary events based on clinical trials involving patients with systolic dysfunction. Its survival benefit in patients with preserved left ventricular ejection fraction (LVEF), is being re-examined. This study assessed the association of beta-blocker therapy prescription and all-cause mortality following a coronary event and percutaneous coronary intervention (PCI), stratified by LVEF. METHODS AND RESULTS: A state-wide nested case-control study of data from the Victorian Cardiac Outcomes Registry linked to the Australian National Death Index (2014-2022) was conducted. Adults discharged alive after PCI were stratified by LVEF: preserved (≥50%), mildly reduced (45-49%), moderately reduced (35-44%), and severely reduced (

Fields of Study & Subjects

Acute Myocardial Infarction Research Heart rate and cardiovascular health Blood Pressure and Hypertension Studies

Publication details

Journal / source
Current Problems in Cardiology
Publisher
Elsevier BV
Volume
51
Issue
8
Pages
103340–103340
Publication date
3 April 2026
Language
EN